Rheumatoid Arthritis Clinical Trials

Many RA trials do require an inadequate response to methotrexate as an eligibility criterion, since this mirrors real-world treatment sequencing. However, other trials specifically enroll methotrexate-naive patients or those who cannot take methotrexate. Some early RA trials enroll patients who have never taken any DMARD. Your treatment history will help identify which trials match your situation.

Trial protocols include provisions for managing disease flares, which may include short courses of corticosteroids, dose adjustments, or rescue medications. If your RA worsens significantly despite these measures, the study team can withdraw you from the trial and transition you to appropriate standard treatment. Your joint health is actively monitored at every visit.

In addition to standard X-rays, many RA trials use musculoskeletal ultrasound and MRI to detect subtle inflammation (synovitis) and early erosions that are invisible on physical examination and plain X-rays. These advanced imaging studies are provided at no cost as part of the trial and give a more detailed assessment of your joint health.

Many RA trials allow background methotrexate and sometimes low-dose corticosteroids while testing the investigational treatment as an add-on. Other trials require washout from specific medications, particularly biologics, before starting the study drug. The washout period varies by medication and trial protocol. Your study team will explain all medication requirements during screening.